Insulin pen use for type 2 diabetes - A clinical perspective

Diabetes Technology and Therapeutics

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Bailey, Timothy S ^a   Edelman, Steven V ^b  

^a AMCR Institute   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN LISPRO;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DISPOSABLE EQUIPMENT; EQUIPMENT DESIGN; HEALTH CARE ACCESS; HEALTH PERSONNEL ATTITUDE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTERMETHOD COMPARISON; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; PATIENT SAFETY; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MARKETING; NEEDLES; PERCEPTION;

EID: 77956161776     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0032     Document Type: Review

References (22)

1. Bode BW: Insulin pump use in type 2 diabetes. Diabetes Technol Ther 2010;12(Suppl 1):S-00-S-00.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
4. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080-3086.
5. Edelman SV, Henry RR: Diagnosis and Management of Type 2 Diabetes, 9th ed. Greenwich, CT: Professional Communications, Inc. , 2007.
6. Grajower MM, Fraser CG, Holcombe JH, Daugherty ML, Harris WC, De Felippis MR, Santiago OM, Clark NG: How long should insulin be used once a vial is started? Diabetes Care 2003;26:2665-2669.
7. Asakura T, Seino H, Nakano R, Muto T, Toraishi K, Sako Y, Kageyama M, Yohkoh N: A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther 2009;11:657-661.
8. Rubin RR, Peyrot M: Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (as-part protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004;27:2495-2497.
9. Jefferson IG, Marteau TM, Smith MA, Baum JD: A multiple injection regimen using an insulin injection pen and pre-filled cartridged soluble human insulin in adolescents with diabetes. Diabet Med 1985;2:493-495.
10. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team: A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848.
11. Davis EM, Bebee A, Crawford L, Destache C: Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educ 2009;35:799-809.
12. Asamoah E: Insulin pen-the "iPod" for insulin delivery (why pen wins over syringe). J Diabetes Sci Technol 2008;2: 292-296.
13. Perfetti R: Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther 2010;12(Suppl 1):S79-S85.
14. Siegmund T, Blankenfeld H, Schumm-Draeger PM: Comparison of usability and patient preference for insulin pen needles produced with different production techniques: "thin-wall" needles compared to "regular-wall" needles: an open-label study. Diabetes Technol Ther 2009;11:523-528.
15. Laurent A, Mistretta F, Bottigioli D, Dahel K, Goujon C, Nicolas JF, Hennino A, Laurent PE: Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007;25:6423-6430.
16. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB: Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006;29:504-509.
17. American Diabetes Association: Insulin administration. Diabetes Care 2004;27(Suppl 1):S106-S109.
18. Yakushiji F, Fujita H, Terayama Y, Yasuda M, Nagasawa K, Shimojo M, Taniguchi K, Fujiki K, Tomiyama J, Kinoshita H: The best insulin injection pen device for caregivers: results of injection trials using five insulin injection devices. Diabetes Technol Ther 2010;12:143-148.
19. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care 2005;28:1282-1288.
20. Le Floch JP, Herbreteau C, Lange F, Perlemuter L: Evidence of non-inert material in needles and cartridges following a single insulin injection with a pen. Diabetes Metab 1997;23: 228-229.
21. Ginsberg BH, Parkes JL, Sparacino C: The kinetics of insulin administration by insulin pens. Horm Metab Res 1994;26: 584-587.
22. Cochran E, Gorden P: Use of U-500 insulin in the treatment of severe insulin resistance. Insulin 2008;3:211-218.